The influence of the pleiotropic action of erythropoietin and its derivatives on nephroprotection

Medical Science Monitor

Volumn 19, Issue 1, 2013, Pages 599-605

  Bartnicki, Piotr ^a   Kowalczyk, Mariusz ^a   Rysz, Jacek ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Anemia; Chronic kidney disease; Erythropoiesis stimulating agents; Erythropoietin; Nephroprotection

Indexed keywords

C REACTIVE PROTEIN; CASPASE 3; CASPASE 9; ERYTHROPOIETIN; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 6; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OXIDOPAMINE; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROTEIN BAX; PROTEIN BCL 2; STAT PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ACUTE KIDNEY FAILURE; APOPTOSIS; ARTICLE; BIOLOGICAL ACTIVITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; DRUG MEGADOSE; FIBROSING ALVEOLITIS; FIBROSIS; GENE EXPRESSION; HEART FUNCTION; HUMAN; INFLAMMATION; LOW DRUG DOSE; NONHUMAN; OXIDATIVE STRESS; PLEIOTROPY; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION;

APOPTOSIS; ERYTHROPOIETIN; HUMANS; INFLAMMATION; KIDNEY; OXIDATIVE STRESS; PROTECTIVE AGENTS;

EID: 84880757091     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.889023     Document Type: Article

References (73)

1. Carnot P, Deflandre C: Sur [Haemopoietic activity of the serum in blood regeneration]. CR Acad Sci, 1906; 143: 384-86
2. Bonsdorff E, Jolavisto E: A humoral mechanism in anoxic erythrocytosis. Acta Physiologica Scandynavica, 1948; 16(2-3): 150-70
3. Erslev A: Humoral regulation of red cell production. Blood, 1953; 8(4): 349-57
4. Goldwasser E: Erythropoietin: a somewhat personal history. Perspect Biol Med, 1996; 40(1): 18-32
5. Lin FK, Suggs S, Lin CH et al: Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci USA, 1985; 82(22): 7580-84
6. Jacobs K, Shoemaker C, Rudersdorf R et al: Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature, 1985; 313(6005): 806-10
7. Winearls CG, Oliver DO, Pippard MJ et al: Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet, 1986; 2(8517): 1175-78
8. Eschbach JW, Adamson JW: Recombinant human erythropoietin: implications for nephrology. Am J Kidney Dis, 1988; 11(3): 203-9
9. Bachmann S, Le Hir M, Eckardt KU: Co-localization of erythropoietin mRNA and ecto-5'-nucleotidase immunoreactivity in peritubular cells of rat renal cortex indicates that fibroblasts produce erythropoietin. J Histochem Cytochem, 1993; 41(3): 335-41
10. Westenfelder C: Unexpected renal actions of erythropoietin. Exp Nephrol, 2002; 10: 294-98
11. Jelkmann W: Erythropoietin: structure, control of production, and function. Physiol Rev, 1992; 72(2): 449-89
12. Jelkmann W: Regulation of erythropoietin production. J Physiol, 2011; 589: 1251-58
13. Lacombe C, Mayeux P: The molecular biology of erythropoietin. Nephrol Dial Transplant, 1999; 14: 22-28
14. Egrie JC, Browne JK: Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer, 2001; 84(Suppl.1): 3-10
15. Catlin DH, Breidbach A, Elliott S, Glaspy J: Comparison of the isoelectric focusing patterns of darbepoetin alfa, recombinant human erythropoietin, and endogenous erythropoietin from human urine. Clin Chem, 2002; 48(11): 2057-59
16. Macdougall IC: CERA (Continuous Erythropoietin Receptor Activator): a new erythropoiesis-stimulating agent for the treatment of anemia. Curr Hematol Rep, 2005; 4(6): 436-40
17. Macdougall IC, Ashenden M: Current and upcoming erythropoiesis-stimulating agents, iron products, and other novel anemia medications. Adv Chronic Kidney Dis, 2009; 16: 117-30
18. Stompor T, Całka A, Grllert R et al: Binocrit-follow-on biologic erytropoetin alpha in the treatment of renal anemia. Forum Nefrologiczne, 2011; 4(3): 277-83
19. Jones SS, D'Andrea AD, Haines LL, Wong GG: Human erythropoietin receptor: cloning, expression, and biologic characterization. Blood, 1990; 76(1): 31-35
20. Bodo E, Kromminga A, Funk W et al: Human hair follicles are an extrarenal source and a nonhematopoietic target of erythropoietin. Faseb Journal, 2007; 21: 3346-54
21. Monge Naldi A, Gassmann M, Bodmer D: Erythropoietin but not VEGF has a protective effect on auditory hair cells in the inner ear. Cell Mol Life Sci, 2009; 66(22): 3595-99
22. Lisowska KA, Debska-Slizien A, Bryl E et al: Erythropoietin receptor is expressed on human peripheral blood T and B lymphocytes and monocytes and is modulated by recombinant human erythropoietin treatment. Artif Organs, 2010; 34: 654-62
23. Bernhardt WM, Eckardt KU: Physiological basis for the use of erythropoietin in critically ill patients at risk for acute kidney injury. Current Opinion in Critical Care, 2008; 14(6): 621-26
24. Johnson DW, Pat B, Vesey DA et al: Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure. Kidney Int, 2006; 69: 1806-13
25. Bahlmann FH, Fliser D: Erythropoietin and renoprotection. Curr Opin Nephrol Hypertens, 2009; 18(1): 15-20
26. Gluba A, Banach M, Hannam S et al: The role of Toll-like receptors in renal diseases. Nat Rev Nephrol. 2010; 6(4): 224-35
27. Endre ZH, Walker RJ, Pickering JW et al: Early intervention with erythropoietin does not affect the outcome of acute kidney injury (the EARLYARF trial). Kidney Int, 2010; 77: 1020-30
28. Kowalczyk M, Banach M, Mikhailidis DP, Rysz J: Erythropoietin update 2011. Med Sci Monit, 2011; 17(11): RA240-47
29. Malyszko J: Biomarkers of acute kidney injury in different clinical settings: a time to change the paradigm? Kidney Blood Press Res, 2010; 33: 368-82
30. Drueke TB, Locatelli F, Clyne N et al: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med, 2006: 335: 2071-84
31. Gouva C, Nikolopoulos P, Ioannidis JP, Siamopoulos KC: Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int, 2004; 66: 753-60
32. Lawler PR, Filion KB, Eisenberg MJ: Correcting Anemia in Heart Failure: The Efficacy and Safety of Erythropoiesis-Stimulating Agents. J Card Fail, 2010; 16(8): 649-58
33. Parfrey PS, Lauve M, Latremouille-Viau D, Lefebvre P: Erythropoietin Therapy and Left Ventricular Mass Index in CKD and ESRD Patients: A Meta-Analysis. Clin J Am Soc Nephrol, 2009; 4(4): 755-62
34. Banach M, Rysz J: Current problems in hypertension and nephrology. Expert Opin Pharmacother, 2010; (11): 2575-78
35. Urao N, Okigaki M, Yamada H et al: Erythropoietin-mobilized endothelial progenitors enhance reendothelialization via Akt-endothelial nitric oxide synthase activation and prevent neointimal hyperplasia. Circ Res, 2006; 98: 1405-13
36. Kao RL, Martin CM, Xenocostas A et al: Erythropoietin improves skeletal muscle microcirculation through the activation of eNOS in a mouse sepsis model. J Trauma, 2011; 71(5 Suppl.1): S462-67
37. Najjar SS, Rao SV, Melloni C et al: Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial. JAMA, 2011; 305(18): 1863-72
38. Warren JS, Zhao Y, Yung R, Desai A: Recombinant human erythropoietin suppresses endothelial cell apoptosis and reduces the ratio of Bax to Bcl-2 proteins in the aortas of apolipoprotein E-deficient mice. J Cardiovasc Pharmacol, 2011; 57(4): 424-33
39. Rysz J, Aronow WS, Stolarek RS, Hannam S et al: Nephroprotective and clinical potential of statins in dialyzed patients. Expert Opin Ther Targets, 2009; 13(5): 541-50
40. Koc M, Dogan C, Arinsoy T et al: Statin use is associated with lower inflammation and erythropoietin responsiveness index in hemodialysis patients. Hemodial Int, 2011; 15(3): 366-73
41. Rysz J, Banach M, Cialkowska-Rysz A et al: Blood serum levels of IL-2, IL-6, IL-8, TNF-alpha and IL-1beta in patients on maintenance hemodialysis. Cell Mol Immunol, 2006; 3(2): 151-54
42. Barreto DV, Barreto FC, Liabeuf S et al: Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. Kidney Int, 2010; 77(6): 550-56
43. Lavin-Gomez BA, Palomar-Fontanet R, Gago-Fraile M et al: Inflammation markers, chronic kidney disease, and renal replacement therapy. Adv Perit Dial, 2011; 27: 33-37
44. Meuwese CL, Stenvinkel P, Dekker FW, Carrero JJ: Monitoring of inflammation in patients on dialysis: forewarned is forearmed. Nat Rev Nephrol, 2011; 7(3): 166-76
45. Ringoir S: An update on uremic toxins. Kidney Int Suppl, 1997; 62: S2-4
46. Debska-Slizien A, Rutkowski B, Manitius J et al: [Influence of erythropoietin on immunological system of patients with chronic renal failure]. Pol Merkur Lekarski, 2003; 15(88): 326-27; discussion 327-29
47. Faquin WC, Schneider TJ, Goldberg MA: Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood, 1992; 79(8): 1987-94
48. Vannucchi AM, Grossi A, Rafanelli D et al: Inhibition of erythropoietin production in vitro by human interferon gamma. Br J Haematol, 1994; 87(1): 18-23
49. Gupta S, Gollapudi S: Molecular mechanisms of TNF-alpha-induced apoptosis in aging human T cell subsets. Int J Biochem Cell Biol, 2005; 37(5): 1034-42
50. Pregi N, Wenker S, Vittori D et al: TNF-alpha-induced apoptosis is prevented by erythropoietin treatment on SH-SY5Y cells. Exp Cell Res, 2009; 315(3): 419-31
51. Ashkenazi A: Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer, 2002; 2(6): 420-30
52. Morceau F, Dicato M, Diederich M: Pro-Inflammatory Cytokine-Mediated Anemia: Regarding Molecular Mechanisms of Erythropoiesis. Mediators Inflamm, 2009; 2009: 405016
53. Contaldo C, Lindenblatt N, Elsherbiny A et al: Erythropoietin requires endothelial nitric oxide synthase to counteract TNF-[alpha]-induced microcirculatory dysfunction in murine striated muscle. Shock, 2011; 35(3): 315-21
54. Hamano Y, Aoki T, Shirai R et al: Low-dose darbepoetin alpha attenuates progression of a mouse model of aristolochic acid nephropathy through early tubular protection. Nephron Exp Nephrol, 2010; 114(2): e69-81
55. Bahlmann FH, Song R, Boehm SM et al: Low-dose therapy with the longacting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure. Circulation, 2004; 110(8): 1006-12
56. Lee SH, Li C, Lim SW et al: Attenuation of interstitial inflammation and fibrosis by recombinant human erythropoietin in chronic cyclosporine nephropathy. Am J Nephrol, 2005; 25(1): 64-76
57. Pedzik A, Paradowski M, Rysz J: [Oxidative stress in nephrology]. Pol Merkur Lekarski, 2010; 28(163): 56-60
58. Ha H, Lee HB: Oxidative stress in diabetic nephropathy: basic and clinical information. Curr Diab Rep, 2001; 1(3): 282-87
59. Ha H, Park J, Kim YS, Endou H: Oxidative stress and chronic allograft nephropathy. Yonsei Med J, 2004; 45(6): 1049-52
60. Dang J, Jia R, Tu Y et al: Erythropoietin prevents reactive oxygen species generation and renal tubular cell apoptosis at high glucose level. Biomed Pharmacother, 2010; 64(10): 681-85
61. De Beuf A, Hou XH, D'Haese PC, Verhulst A: Epoetin delta reduces oxidative stress in primary human renal tubular cells. J Biomed Biotechnol, 2010; 2010: 395785
62. Wojchowski DM, Sathyanarayana P, Dev A: Erythropoietin receptor response circuits. Curr Opin Hematol, 2010; 17(3): 169-76
63. Hu Y, Benedict MA, Wu D, Inohara N, Nunez G: Bcl-XL interacts with Apaf-1 and inhibits Apaf-1-dependent caspase-9 activation. Proc Natl Acad Sci USA, 1998; 95(8): 4386-91
64. Pan G, O'Rourke K, Dixit VM: Caspase-9, Bcl-XL, and Apaf-1 form a ternary complex. J Biol Chem, 1998; 273(10): 5841-45
65. Cassis P, Gallon L, Benigni A et al: Erythropoietin, but not the correction of anemia alone, protects from chronic kidney allograft injury. Kidney Int, 2012; 81(9): 903-18
66. Liu N, Tian J, Wang W, Cheng J et al: Effect and mechanism of erythropoietin on mesenchymal stem cell proliferation in vitro under the acute kidney injury microenvironment. Exp Biol Med (Maywood), 2011; 236(9): 1093-99
67. Ge XH, Zhu GJ, Geng DQ et al: Erythropoietin attenuates 6-hydroxydopamine-induced apoptosis via glycogen synthase kinase 3beta-mediated mitochondrial translocation of Bax in PC12 cells. Neurol Sci, 2012; 33(6): 1249-56
68. Ngo K, Kotecha D, Walters JA et al: Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients. Cochrane Database Syst Rev, 2010; (1): CD007613
69. Silverberg DS, Wexler D, Iaina A et al: Anemia, chronic renal disease and congestive heart failure-the cardio renal anemia syndrome: the need for cooperation between cardiologists and nephrologists. Int Urol Nephrol, 2006; 38(2): 295-310
70. Snaedal S, Heimburger O, Qureshi AR et al: Comorbidity and acute clinical events as determinants of C-reactive protein variation in hemodialysis patients: implications for patient survival. Am J Kidney Dis, 2009; 53(6): 1024-33
71. Villa G: [Erythropoiesis-stimulating agents: from the origins to new challenges]. G Ital Nefrol, 2010; 27(Suppl.52): S38-46
72. Foundation NK: KDOQI Clinical Practice Guidelines and Clinical Practice Recomendations For Anemia in Chronic Kidney Disease. Am J Kidney Dis, 2006; 47(5): Suppl 3
73. Anaemia Management in Chronic Kidney Disease: Rapid Update 2011. London: National Clinical Guideline Centre.; 2011. [Internet]